Search
FDA's Revolutionary New Policy: Abandoning Animal Testing, Leveraging Organoids and AI to Initiate a New Era in Biomedical R&D
2025-04-14 /
Read about 0 minute
Author：小编
The Food and Drug Administration (FDA) has unveiled a groundbreaking policy to phase out traditional animal testing in the development of monoclonal antibody drugs. This shift embraces innovative technologies, including AI computational models, cell line testing, and organoid toxicity assessments. The objective is to expedite drug development, minimize costs, and elevate the efficacy of research methodologies and clinical trials. This policy transformation heralds fresh prospects in the realms of cellular and gene therapy.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
